Nika Pharmaceuticals, Inc.
NIKA
$0.41
-$0.01-2.38%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 49.81% | 36.59% | -14.54% | -38.48% | -39.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.81% | 36.59% | -14.54% | -38.48% | -39.23% |
| Operating Income | -49.81% | -36.59% | 14.54% | 38.48% | 39.23% |
| Income Before Tax | -49.81% | -36.59% | 14.54% | 38.48% | 39.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -49.81% | -36.59% | 14.54% | 38.48% | 39.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.81% | -36.59% | 14.54% | 38.48% | 39.23% |
| EBIT | -49.81% | -36.59% | 14.54% | 38.48% | 39.23% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -- | -- | 100.00% | 100.00% | 100.00% |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | 100.00% | 100.00% | 100.00% |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 2.66% | 2.24% | 5.57% | 8.83% | 12.49% |
| Average Diluted Shares Outstanding | 2.66% | 2.24% | 5.57% | 8.83% | 12.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |